Dimerix Limited
Dimerix Limited
Your view on DXB.AX
Overview
What the company does, where it operates, and who runs it.
About Dimerix Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Nina Webster
- Headquarters
- 425 Smith Street, Fitzroy, VIC, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Nina Webster
- Headquarters
- 425 Smith Street, Fitzroy, VIC, AU
Dimerix Limited is an Australian biopharmaceutical firm dedicated to discovering and bringing to market innovative pharmaceutical solutions for medical conditions where existing treatments are insufficient. The company's leading therapeutic candidate, DMX-200, is currently undergoing extensive clinical evaluation, including two separate Phase 3 trials targeting respiratory complications linked to COVID-19. DMX-200 is also in a distinct Phase 3 clinical trial for focal segmental glomerulosclerosis (FSGS), a severe kidney disorder, and is being developed for the treatment of diabetic kidney disease. Additionally, Dimerix is advancing DMX-700, which is intended for chronic obstructive pulmonary disease (COPD). The company's corporate headquarters are located in Fitzroy, Australia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Dimerix Limited, and the rating behind it. DXB.AX last traded at AUD 0.28; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Dimerix Limited. Starting points for Dimerix Limited: EPS -AUD 0.03, beta 0.34 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Dimerix Limited. Dimerix Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Dimerix Limited. Trailing twelve-month EPS for Dimerix Limited stands at -AUD 0.03. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Dimerix Limited. Dimerix Limited has reported as a listed company since 1989. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Dimerix Limited valued side by side against its closest peers. Dimerix Limited is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Dimerix Limited, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Dimerix Limited executives and directors. Shares of Dimerix Limited have traded between AUD 0.16 and AUD 0.67 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Dimerix Limited. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Dimerix Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Dimerix Limited. Coverage tracks Dimerix Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.